For pharma, diagnosing what ails or strengthens performance in this critical corporate discipline may help reshape business prognosis.
Richard M. Bayney
Advertisement
Articles by Richard M. Bayney
Advertisement
Latest Updated Articles
Portfolio Management Health CheckMay 12th 2017
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership
2
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
3
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
4
What the Peptide Advisory Vote Actually Means: Q&A with James LaValle
5